Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7,306 JPY | +2.21% | +2.70% | +7.47% |
Business Summary
- prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.;
- OTC products: analgesic products, vitamins and tonics, etc.;
- diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Number of employees: 5,680
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 335,138 | 100.0 % | 426,684 | 100.0 % | +27.32% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
48.7
%
| 113,589 | 33.9 % | 207,777 | 48.7 % | +82.92% |
United Kingdom
40.9
%
| 184,202 | 55.0 % | 174,706 | 40.9 % | -5.16% |
Other
4.1
%
| 15,587 | 4.7 % | 17,670 | 4.1 % | +13.36% |
United States
3.8
%
| 14,322 | 4.3 % | 16,247 | 3.8 % | +13.44% |
Europe
2.4
%
| 7,427 | 2.2 % | 10,276 | 2.4 % | +38.36% |
North America
0.0
%
| 8 | 0.0 % | 6 | 0.0 % | -25.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Isao Teshirogi
CEO | Chief Executive Officer | 64 | 82-03-31 |
Yuji Hosogai
DFI | Director of Finance/CFO | - | - |
Yasuetsu Imune
CTO | Chief Tech/Sci/R&D Officer | - | - |
John Keller
CTO | Chief Tech/Sci/R&D Officer | - | - |
Takuko Sawada
BRD | Director/Board Member | 69 | 77-03-31 |
Yoshinori Yurugi
PRN | Corporate Officer/Principal | - | - |
Aki Ikehata
LAW | General Counsel | - | - |
Human Resources Officer | - | - | |
Harumi Shimai
SAM | Sales & Marketing | - | - |
Takeshi Shiota
PRN | Corporate Officer/Principal | - | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Hiroshi Ozaki
BRD | Director/Board Member | 74 | 19-05-31 |
Isao Teshirogi
CEO | Chief Executive Officer | 64 | 82-03-31 |
Takuko Sawada
BRD | Director/Board Member | 69 | 77-03-31 |
Keiichi Ando
BRD | Director/Board Member | 72 | 16-05-31 |
Fumi Takatsuki
BRD | Director/Board Member | 48 | 20-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 296,544,065 | 262,150,439 ( 88.40 %) | 20,053,452 ( 6.762 %) | 88.40 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SHIONOGI & CO., LTD. 3.39% | 10,052,488 | 3.39% | 514,762,880 $ |
1,643,810 | 0.12% | 96,763,714 $ | |
TOHO HOLDINGS CO., LTD. 4.58% | 3,500,000 | 4.58% | 84,456,050 $ |
SUZUKEN CO., LTD. 2.13% | 1,656,696 | 2.13% | 50,780,748 $ |
914,000 | 1.85% | 21,348,508 $ | |
1,271,605 | 0.57% | 19,492,700 $ | |
KANEKA CORPORATION 0.40% | 266,600 | 0.40% | 6,718,507 $ |
STEMRIM 2.93% | 1,800,000 | 2.93% | 5,827,752 $ |
344,095 | 0.07% | 5,580,502 $ | |
210,420 | 0.03% | 4,599,224 $ |
Company contact information
Shionogi & Co., Ltd.
3-1-8 Dosho-machi Chuo-Ku
541-0045, Osaka
+81 6 6202 2161
http://www.shionogi.co.jpSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.47% | 13.16B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4507 Stock
- Company Shionogi & Co., Ltd.